The FDA is still reviewing the EUA submission for Moderna’s booster shot, where the only remaining issue is the dose. MRNA thinks a dose half as much as the dose used for the first two shots would suffice for the booster, but the FDA may want to go with the full dose. An advisory committee will hash this out.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.